« AGS Therapeutics Strengthens its Patent Portfolio on Microalgae Extracelluar Vesicles (MEV) with an International Patent Application on Biodistribution and Uses of MEVs as Delivery System to Reach Difficult to Access Tissues », Paris, FR, August 7, 2023.

AGS Therapeutics Strengthens its Patent Portfolio on Microalgae Extracellular Vesicles (MEV) with an International Patent Application on Biodistribution and Uses of MEVs as Universal Delivery System to Reach Difficult-to-Access Tissues.

MEVs can be seen as a universal delivery system for innovative therapeutics, and  as a non-viral gene therapy vector. MEVs can be exo-loaded with all kinds of  therapeutic modalities for delivery through multiple modes of administration.  They overcome stringent biological barriers and reach difficult to access tissues,  providing the potential to overcome challenges faced by other delivery systems. 

International Patent Application on Biodistribution and Uses of MEVs as Delivery System to Reach Difficult to Access Tissues - AGS©2023
International Patent Application on Biodistribution and Uses of MEVs as Delivery System to Reach Difficult to Access Tissues - AGS©2023

PARIS, FRANCE, August 7, 2023 – AGS Therapeutics, a preclinical-stage biotech company pioneering microalgae extracellular vesicles (MEV) as a new delivery system for innovative  therapeutics, announced the recent publication of its PCT Application No.  PCT/EP2023/051650 - Publication - WO2023144127, entitled Extracellular Vesicles from  Microalgae, their Biodistribution upon Administration, and Uses

“MEVs can be efficiently exo-loaded with either mRNA, siRNA, plasmid-DNA, ASO,  peptides, or proteins, and can be used to deliver their payloads to various specific tissues and  organs, which have been so far either difficult or impossible to access by current alternative  systems like mammalian EVs, LNPs, or viral gene therapy vectors” said AGS Chief Operating  Officer Lila Drittanti.  

The published patent application highlights the rare capacity of MEVs to overcome biological  barriers, and to deliver biologically active payloads to so far difficult-to-access tissues. - When orally administered, MEVs pass through the stringent conditions of the stomach and, after reaching the intestine, they deliver their payload in the enterocytes of the intestinal  epithelium. In a world’s first, we have shown that mRNA can be delivered and expressed in  the intestine upon oral administration. Furthermore, active enzymes loaded in MEVs keep their biological activity after oral administration and delivery.

- When administered intratracheally, MEVs can be used to deliver their biologically active  payload, which is expressed in the lungs as demonstrated for mRNA and proteins.

- When administered topically on the eye surface, by drop instillation, MEVs deliver their  payload in the choroid-retina. 

- When administered intranasally, MEVs elicit nose-to-brain delivery, reaching the brain and  travelling throughout the olfactory network into most of the brain regions relevant to diseases. 

These findings highlight the breakthrough of MEVs as universal delivery system. 

“None of the alternative delivery systems, currently available or in development, has  demonstrated such versatility in the biodistribution, routes of administration, nor the capacity  to efficiently overcome so many biological barriers”, said AGS Chief Corporate Development  Marie-Hélène Leopold. “MEVs have naturally evolved over 2-3 billion years and have thus  naturally become a highly sophisticated vector that can be exploited for the delivery of  therapeutics”. 

AGS’ portfolio of Intellectual Property is managed by Stephanie Seidman, at Dentons’ LLC,  San Diego (www.dentons.com/en/stephanie-seidman). 

About AGS 

AGS Therapeutics, based in Paris, France, is a biotech company pioneering the development  of biomedicines based on extracellular vesicles from microalgae (MEV). MEVs have been  shown to be a safe, targeted and highly versatile delivery system and non-viral gene therapy  vector, for innovative biologics, such as mRNA, siRNA, DNA, plasmids, and proteins for a  broad range of human diseases. AGS-M, the company’s subsidiary and a contract development  and manufacturing organisation, will produce the MEVs needed to support preclinical and  clinical development of product pipelines from AGS and from pharmaceutical companies  partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single cell algae used for decades as a food supplement. Chlorella is FDA-labeled as GRAS for  consumption as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with  processes that are both eco-friendly and easily scalable. Through strategic partnerships and a commitment to scientific excellence, the company aims to challenge the delivery landscape  and improve the lives of patients across the globe. For more information visit www.ags-tx.com and www.ags-m.com. 

Forward looking statement 

This announcement may include predictions, estimates or other information that might be  considered forward-looking. While these forward-looking statements represent our current  judgment on what the future holds, they are subject to risks and uncertainties that could cause  actual results to differ materially. You are cautioned not to place undue reliance on these  forward-looking statements, which reflect our opinions only as of the date of this  communication.  

Contacts - US:

Dan Eramian

Opus Biotech Communications

+1 425-306-8716


Charles Craig

Opus Biotech Communications

+1 404-245-0591


Contacts - Europe:

Ana Vega

Markets & Listing 

+33 (0)6 88 57 05 77


Marie-Hélène Leopold

AGS Therapeutics

+33 (0)6 07 16 55 01


No items found.